全文获取类型
收费全文 | 1732篇 |
免费 | 95篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 56篇 |
妇产科学 | 42篇 |
基础医学 | 159篇 |
口腔科学 | 47篇 |
临床医学 | 165篇 |
内科学 | 288篇 |
皮肤病学 | 53篇 |
神经病学 | 114篇 |
特种医学 | 52篇 |
外科学 | 253篇 |
综合类 | 46篇 |
一般理论 | 1篇 |
预防医学 | 106篇 |
眼科学 | 78篇 |
药学 | 209篇 |
中国医学 | 25篇 |
肿瘤学 | 135篇 |
出版年
2024年 | 2篇 |
2023年 | 29篇 |
2022年 | 55篇 |
2021年 | 109篇 |
2020年 | 71篇 |
2019年 | 139篇 |
2018年 | 97篇 |
2017年 | 64篇 |
2016年 | 83篇 |
2015年 | 73篇 |
2014年 | 83篇 |
2013年 | 107篇 |
2012年 | 138篇 |
2011年 | 138篇 |
2010年 | 68篇 |
2009年 | 65篇 |
2008年 | 77篇 |
2007年 | 77篇 |
2006年 | 72篇 |
2005年 | 39篇 |
2004年 | 36篇 |
2003年 | 24篇 |
2002年 | 25篇 |
2001年 | 14篇 |
2000年 | 7篇 |
1999年 | 12篇 |
1998年 | 4篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 12篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 9篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1979年 | 5篇 |
1975年 | 4篇 |
1974年 | 4篇 |
1971年 | 4篇 |
1967年 | 1篇 |
1965年 | 2篇 |
排序方式: 共有1840条查询结果,搜索用时 62 毫秒
41.
42.
Al-Herz Adeeba Saleh Khuloud Al-Awadhi Adel Al-Kandari Waleed Hasan Eman Ghanem Aqeel Hussain Mohammed Ali Yaser Nahar Ebrahim Alenizi Ahmad Hayat Sawsan Abutiban Fatemah Aldei Ali Alhajeri Hebah Alhadhood Naser Bahbahani Husain Tarakmeh Hoda Mokaddem Khaled Khadrawy Ahmad Fazal Ammad Zaman Agaz Mazloum Ghada Bartella Youssef Hamed Sally Alsouk Ramia Al-Saber Ahmed 《Clinical rheumatology》2021,40(5):1759-1765
Clinical Rheumatology - Biologics are indicated in rheumatoid arthritis (RA) in case of persistent high disease activity despite conventional disease-modifying anti-rheumatic drugs (cDMARDs) or... 相似文献
43.
Mohammad Abd Alkhalik Basha Hossam M. Abdelrahman Maha Ibrahime Metwally Nader Ali Alayouty Nesreen Mohey Mohamed M.A. Zaitoun Hosam Nabil Almassry Hala Y. Yousef Ahmed A. El Sammak Sameh Abdelaziz Aly Hesham Youssef Algazzar Mohamed Abd El‐Aziz Mohamed Farag Walid Mosallam Waleed S. Abo Shanab Safaa A. Ibrahim Ekramy A. Mohamed Abd El Motaleb Mohamed Amira Hamed Mohamed Afifi Ola A. Harb Taghreed M. Azmy 《Journal of magnetic resonance imaging : JMRI》2021,53(1):292-304
44.
45.
46.
Gerard M O'Reilly Rob D Mitchell Biswadev Mitra Hamed Akhlaghi Viet Tran Jeremy S Furyk Paul Buntine Holly Bannon‐Murphy Timothy Amos Maushmi Udaya Kumar Emma Perkins Alexandra Prentice Olivia Szwarcberg Ashley Loughman Nicole Lowry Steven Colwell Michael P Noonan Ryan Hiller Andrew Paton De Villiers Smit Peter A Cameron 《Emergency medicine Australasia : EMA》2021,33(1):114-124
47.
48.
Quique Bassat Bernhards Ogutu Abdoulaye Djimde Kirstin Stricker Kamal Hamed 《Antimicrobial agents and chemotherapy》2015,59(8):4366-4374
Specially created pediatric formulations have the potential to improve the acceptability, effectiveness, and accuracy of dosing of artemisinin-based combination therapy (ACT) in young children, a patient group that is inherently vulnerable to malaria. Artemether-lumefantrine (AL) Dispersible is a pediatric formulation of AL that is specifically tailored for the treatment of children with uncomplicated Plasmodium falciparum malaria, offering benefits relating to efficacy, convenience and acceptance, accuracy of dosing, safety, sterility, stability, and a pharmacokinetic profile and bioequivalence similar to those of crushed and intact AL tablets. However, despite being the first pediatric antimalarial to meet World Health Organization (WHO) specifications for use in infants and children who are ≥5 kg in body weight and its inclusion in WHO Guidelines, there are few publications that focus on AL Dispersible. Based on a systematic review of the recent literature, this paper provides a comprehensive overview of the clinical experience with AL Dispersible to date. A randomized, phase 3 study that compared the efficacy and safety of AL Dispersible to those of crushed AL tablets in 899 African children reported high PCR-corrected cure rates at day 28 (97.8% and 98.5% for AL Dispersible and crushed tablets, respectively), and the results of several subanalyses of these data indicate that this activity is observed regardless of patient weight, food intake, and maximum plasma concentrations of artemether or its active metabolite, dihydroartemisinin. These and other clinical data support the continued use of pediatric antimalarial formulations in all children <5 years of age with uncomplicated malaria when accompanied by continued monitoring for the emergence of resistance. 相似文献
49.
50.